Levofloxacin Actavis (Levofloxacin Hemihydrate)

Levofloxacin blocks bacterial DNA gyrase and topoisomerase IV, enzymes needed for DNA replication and transcription. By inhibiting these enzymes, the drug prevents bacterial cells from multiplying, leading to bacterial death and clearance of the infection.

The dosing regimen for Levofloxacin Actavis is determined by the prescribing clinician based on the severity of the infection, patient age, and ocular condition. The prescriber will specify the number of drops, frequency, and duration of therapy.

Safety data for ocular levofloxacin in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by the treating physician.

To request Levofloxacin Actavis, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Levofloxacin belongs to the fluoroquinolone class, offering broad‑spectrum activity against many Gram‑negative and Gram‑positive ocular pathogens. Compared with older agents such as chloramphenicol or erythromycin, levofloxacin often provides faster bacterial eradication and a lower risk of resistance, though individual choice depends on susceptibility patterns and patient factors.

Levofloxacin Actavis should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from direct sunlight, excessive heat, and moisture to maintain its stability and potency.

Levofloxacin Actavis is administered as an ocular drop or subconjunctival injection, as directed by the prescriber. The recommended technique involves cleaning the eye area, instilling the prescribed number of drops, and allowing the medication to spread without blinking excessively.

Serious risks include severe allergic reactions (anaphylaxis), tendon rupture, and rare central nervous system effects such as seizures. Patients should be instructed to stop the medication and seek immediate medical attention if they experience signs of a serious reaction.

Levofloxacin Actavis should not be used by individuals with a known hypersensitivity to levofloxacin, other fluoroquinolones, or any component of the formulation. Caution is also advised for patients with a history of tendon disorders or those taking interacting medications.